SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-059898
Filing Date
2022-03-01
Accepted
2022-03-01 08:09:03
Documents
14
Period of Report
2022-02-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d286384d8k.htm   iXBRL 8-K 30546
2 EX-99.1 d286384dex991.htm EX-99.1 9476
6 GRAPHIC g286384g0301010253243.jpg GRAPHIC 5431
  Complete submission text file 0001193125-22-059898.txt   179839

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cadl-20220224.xsd EX-101.SCH 2860
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cadl-20220224_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cadl-20220224_pre.xml EX-101.PRE 11710
8 EXTRACTED XBRL INSTANCE DOCUMENT d286384d8k_htm.xml XML 3548
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

IRS No.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40629 | Film No.: 22694077
SIC: 2836 Biological Products, (No Diagnostic Substances)